New research has suggested medication combination can optimize patients’ quality of life… Neural protamine Hagedorn (NPH) is an intermediate insulin that reduces blood glucose levels. Its peak in activity is at 4-6 hours after administration and duration of action is between 12-16 hours. Glargine duration of action is prolonged to …

Proper diabetes education at a young age can reduce amount of common errors… The primary clinical objective to be achieved with insulin therapy initiation is the elimination of ketosis and hyperglycemic events with prevention of chronic problems. Insulin therapy is the primary management of type 1 diabetes, which should be …

Even though metformin delayed release resides in gut, it still maintains glucose-lowering effect… Metformin has been known to be the first line treatment for type 2 diabetes if the side effects are tolerable. According to new study published by Diabetes Care, metformin delayed release (metformin DR) primary effect is in …

Study shows that impaired fasting glucose is less accurate diagnostic tool…   Patients with normal glucose tolerance (NGT) and 1-hour post-load plasma glucose level of ≥155 mg/dl have a higher cardio-metabolic risk profile compared to patients with NGT and impaired glucose tolerance (IGT), according to The Journal of Clinical Endocrinology …

Insulin has different impact on fasting plasma glucose and day-to-day changes… The duration of action for degludec is approximately 42 hours and is much longer than the duration of action of glargine. Due to degludec pharmacokinetics, it leads to a slower absorption rate from the injection site to the blood …

A study supports previous findings that better-educated people have greater access to resources that promote healthy living, such as gym memberships or homes in neighborhoods that encourage walking. Researchers examined data from the U.S. National Health and Nutrition Examination Survey 2007-2012, and found adults with a college degree who were …

Lackluster results for liraglutide as adjunct to insulin therapy: Novo Nordisk announced that it will not pursue an expanded indication for liraglutide (Victoza) as an add-on treatment to insulin for type 1 diabetes because of disappointing phase III trial results. The company released top-line results for the ADJUNCT ONE randomized …

They decided to initiate a phase 3a program with oral semaglutide; a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide. The decision follows the encouraging results of the proof-of-concept phase 2 trial and the subsequent consultations with regulatory authorities. Novo Nordisk intends to initiate a global phase 3a program, …

What every patient needs to have to save their lives. For more information about preparing your diabetes supplies for an emergency, watch this “How to Pack Your Kit” video. A list of what you need from Eli Lilly — English version / Spanish version.  

Empagliflozin/metformin is new combo medication for type 2 diabetes. More information coming in next week’s newsletter.